𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Bornaprine vs placebo in Parkinson disease: double-blind controlled cross-over trial in 30 patients

✍ Scribed by R. Cantello; A. Riccio; M. Gilli; M. Delsedime; L. Scarzella; M. Aguggia; B. Fergamasco

Book ID
105504444
Publisher
Springer Milan
Year
1986
Tongue
English
Weight
357 KB
Volume
7
Category
Article
ISSN
1590-1874

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Intravenous flumazenil for Parkinson's d
Intravenous flumazenil for Parkinson's disease: A single dose, double blind, placebo controlled, cross-over trial
✍ William G. Ondo; Yavuz S. Silay 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

## Abstract Flumazenil is a short‐acting intravenously administered γ‐aminobutyric acid (GABA) antagonist used to reverse the effects of benzodiazepines. Based upon current basal ganglion models in Parkinson's disease (PD), flumazenil could normalize neuronal signaling at several different location

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease
✍ Kitty K. Wong; Jane E. Alty; Amanda G. Goy; Sanjay Raghav; David C. Reutens; Pet 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 565 KB

## Abstract ## Background: This randomized double blind, placebo‐controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease. ## Methods: Sixteen participants with levodopa‐induced dyskinesia were enrolled. Hourly videotaped dyskinesia assessments s

Sarizotan as a treatment for dyskinesias
Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial
✍ Christopher G. Goetz; Philippe Damier; Christine Hicking; Eugene Laska; Thomas M 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 1 views

## Abstract The objective of this study is to conduct a dose‐finding study of sarizotan in Parkinson's disease (PD) patients with dyskinesia to identify a safe dose and to identify a sensitive dyskinesia rating measure. Sarizotan is a novel compound with full 5‐HT~1A~ agonist properties and additio

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients
✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB 👁 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to